By the end of 2018, it was revealed that certain breast implants of the pharmaceutical company Allergan shall not be used in Europe for the time being. Now the company has launched a number of implants, due to possible cancer risk worldwide.

This precautionary measure was recommended after around 500 cases of a rare cancer have been associated with the implants of the manufacturer. Of this, the US food and drug administration (FDA) said on Wednesday (local time).

“A recall is appropriate, in order to protect the health of women,” said the FDA. Women who have no complaints, but it is not recommended to have your implants removed. The first signs of a disease could be the FDA, according to swelling or pain in the area of the implant.

The recall relates to a number of breast implants the Biocell series of the manufacturer. “The health of the patients for the Allergan’s priority,” said the Ireland-based company. The rest of the Allergan breast implants from the ranks Natrelle and Microcell are not affected, therefore, of the recall. Allergan is listed on the New York stock exchange.

In Germany, only a few suspected cases have been reported

An analysis of the FDA, nearly 500 women breast implants of the company Allergan had of the around 600 patients suffering from the rare lymphoma BIA ALCL,. So far, there had been 33 deaths in consequence of cancer, so the FDA.

The first known case of ALCL associated with a breast implant made of silicone has been documented in 1997. A study from the year 2015, according to a patient of up to three million women with breast implants is affected. It is, however, only estimates.

Reliable calculations are hardly possible, since the number of documented cases is not collected centrally. In Germany ten suspected cases of ALCL have been reported, according to the Federal Institute for drugs and medical products until the end of 2018 in connection with a breast implant.